de Melo CSoares, Singh V, Myrick A, Simelane SB, Taylor D, Brunschwig C, Lawrence N, Schnappinger D, Engelhart CA, Kumar A et al..
2021.
Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.. J Med Chem. 64(1):719-740.
Zainabadi K, Walsh KFrances, Vilbrun SCharles, Mathurin LDaniel, Lee MHee, Saito K, Mishra S, Ocheretina O, Pape JWilliam, Nathan C et al..
2021.
Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy.. Antimicrob Agents Chemother. 65(8):e0060821.
Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, Hua Y, Prichard L, Kornbrust AN, Sterrett S et al..
2021.
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.. Cell Rep Med. 2(1):100164.
Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, Hua Y, Prichard L, Kornbrust AN, Sterrett S et al..
2021.
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.. Cell Rep Med. 2(1):100164.
Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, Hua Y, Prichard L, Kornbrust AN, Sterrett S et al..
2021.
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.. Cell Rep Med. 2(1):100164.
Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, Hua Y, Prichard L, Kornbrust AN, Sterrett S et al..
2021.
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.. Cell Rep Med. 2(1):100164.
Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, Toita A, Okamoto R, Wong T-T, Imaeda T et al..
2021.
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.. Angew Chem Int Ed Engl. 60(17):9279-9283.
Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, Toita A, Okamoto R, Wong T-T, Imaeda T et al..
2021.
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.. Angew Chem Int Ed Engl. 60(17):9279-9283.
Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, Toita A, Okamoto R, Wong T-T, Imaeda T et al..
2021.
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.. Angew Chem Int Ed Engl. 60(17):9279-9283.
Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, Toita A, Okamoto R, Wong T-T, Imaeda T et al..
2021.
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.. Angew Chem Int Ed Engl. 60(17):9279-9283.
Lee BShi, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMin Sheril, Manimekalai MSony S, Koh VH et al..
2021.
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.. EMBO Mol Med. 13(1):e13207.
Bosch B, DeJesus MA, Poulton NC, Zhang W, Engelhart CA, Zaveri A, Lavalette S, Ruecker N, Trujillo C, Wallach JB et al..
2021.
Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.. Cell. 184(17):4579-4592.e24.
Bosch B, DeJesus MA, Poulton NC, Zhang W, Engelhart CA, Zaveri A, Lavalette S, Ruecker N, Trujillo C, Wallach JB et al..
2021.
Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.. Cell. 184(17):4579-4592.e24.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..
2021.
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..
2021.
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.